Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 467 participants.
Also called NCT02833844
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 467 participants
- Sponsor
- Registry
-
NCT02833844 -
2015-004735-12
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Brazil, Canada, France, Greece, Italy, Poland, Portugal, Romania, South Africa, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02833844. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-22 (actual); primary completion 2019-07-09 (actual). Results posted on 2020-07-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
- Condition
- Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
- Intervention (Drug)
- Evolocumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02833844- Content hash
fac4f080ec256f031d24b6db89adaca7418022c12bf0117c66acee5937277089